Tipranavir: A new option for the treatment of drug-resistant HIV infection

Clinical Infectious Diseases

Volumn 45, Issue 6, 2007, Pages 761-769

  Temesgen, Zelalem ^a   Feinberg, Judith ^b,c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ERGOT DERIVATIVE; ETRAVIRINE; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; LAMIVUDINE; LOPINAVIR; NEUROLEPTIC AGENT; NEVIRAPINE; PROTEINASE INHIBITOR; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SEDATIVE AGENT; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS RESISTANCE; DEATH; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME INHIBITION; FEMALE; FOOD DRUG INTERACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; RASH; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TOXIC HEPATITIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INFECTION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; VOMITING;

CHOLESTEROL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PYRIDINES; PYRONES; RITONAVIR; TRIGLYCERIDES;

EID: 34548534109     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520847     Document Type: Review

References (56)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
2. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349:1294.
3. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997; 11:F101-5.
4. Palella FJ, Chmiel JS, Mooreman AC, Holmberg SD; the HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16:1617-26.
5. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
6. Thaisrivongs S, Skulnick HI, Turner SR, et al. Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem 1996; 39:4349-53.
7. Larder BA, Hertogs K, Bloor S, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000; 14:1943-8.
8. Schake D. How flexible is tipranavir in complex with the HIV-1 protease active site? AIDS 2004; 18:579-80.
9. Turner SR, Strohbach JW, Tommasi RA, et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998; 41:3467-76.
10. Borin MT, Wang Y, Schneck DW, et al. Multiple-dose, safety, tolerance and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers [abstract 648]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
11. McCallister S, Valdez H, Curry K, et al. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1 infected patients. J Acquir Immune Defic Syndr 2004; 35:376-82.
12. MacGregor TR, Sabo JP, Norris SH, et al. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin Trials 2004; 5:371-82.
13. Yeni P, MacGregor T, Gathe J, et al. Correlation of viral load reduction and plasma levels in multiple protease inhibitor experienced patients taking tipranavir/ritonavir in a phase IIB trial: BI 1182.52 [abstract 528]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2003.
14. Baldwin JR, Boron MT, Wang Y, Schneck DW, Hopkins NK. Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers [abstract 649]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
15. Aptivus [package insert]. Ridgefield, Connecticut: Boehringer Ingelheim Pharmaceuticals. Revised 27 June 2006.
16. Cooper C, van Heeswijk R, Bilodeau M, et al. The pharmacokinetics (PK) of single-dose and steady-state tipranavir/ritonavir (TPV/r) 500 mg/200 mg in subjects with mild or moderate hepatic impairment [abstract TuPe3.1B07]. In: Program and abstacts of the 3rd IAS Conference on HIV Pathogenesis and Treatment. Geneva: International AIDS Society, 2005.
17. Wang Y, Daenzer C, Wood R, et al. The safety, efficacy and viral dynamics analysis of tipranavir, a new-generation protease inhibitor, in a phase II study in antiretroviral-naive HIV-1-infected patients [abstract 673]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2000.
18. Cooper D, Zajdenverg R, Ruxrungtham K, et al. Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naive patients: results of BI 1182.33 [abstract PL 13.4]. In: Program and abstracts of the 8th International Congress on Drug Therapy in HIV Infection. 2006.
19. Neubacher D, Markowitz M, Slater L, Curry R, Kohlbrenner V, McCallister S. Long-term 80-week follow-up of highly treatment-experienced (HTE) patients on tipranavir-based antiretroviral therapy (BI 1182.2) [abstract 7.2/3]. In: Program and abstracts of the 9th European AIDS Conference. 2003.
20. Squires K, McCallister S, Lazzarin A, et al. Tipranavir/ritonavir (TPV/r) demonstrates a robust resistance profile in multiple protease inhibitor-experienced patients: correlation of baseline genotype and antiviral activity in BI 1182.52 [abstract 812]. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Geneva: International AIDS Society, 2003.
21. Gathe J, Kohlbrenner VM, Pierone G, et al. Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52 [abstract 179]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2003.
22. Cooper D, Hicks C, Cahn P, et al. 24-Week RESIST study analyses: the efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen [abstract 560]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
23. Lazzarin A, Mukwaya G, Clumeck N, et al. Tipranavir/ritonavir (TPV/r) demonstrates superior treatment response to lopinavir/r (LPV/r), amprenavir/r (APV/r) or saquinavir/r (SQV/r) in PI-experienced patients from the TPV RESIST-1 and RESIST-2 trials [abstract WePe6.3C07]. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment. Geneva: International AIDS Society, 2005.
24. Tipranavir capsules, NDA 21-814. Applicant: Boehringer Ingelheim Pharmaceuticals. Antiviral Drugs Advisory Committee (AVDAC) briefing document, 19 April 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/ briefing/2005-4139b1-02-boehringer.pdf. Accessed 15 March 2006.
25. Grinsztejn B, Hicks C, Cahn P, et al. Tipranavir/ritonavir (TPV/r) demonstrates superior immunologic response to comparator protease inhibitors (CPIs) in a PI-experienced population with advanced disease [abstract WePe16.7B07]. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment. Geneva: International AIDS Society, 2005.
26. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466-75.
27. Katlama C, Walmsley S, Hicks C, et al. Tipranavir achieves twice the rate of treatment response and prolongs durability of response vs. comparator PI in ART-experienced patients, independent of baseline CD4 cell count or viral load: week 48 RESIST 1 and 2 combined analyses [abstract 520]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
28. Schapiro J, Cahn P, Trottier B, et al. Effect of baseline genotype on response to tipranavir/ritonavir (TPV/r) compared with standard-of-care comparator (CPI/r) in treatment-experienced patients: the phase 3 RESIST-1 and -2 trials [abstract 104]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
29. Lazzarin A, Feinberg J, Kraft M, Hall D. Week 48 efficacy of TPV/r treatment is enhanced in patients with higher numbers of genotypically available background drugs in RESIST 1 and 2 [abstract P24]. In: Program and abstracts of the 8th International Congress on Drug Therapy in HIV Infection. 2006. Available at: http://www.abstracts2view.com/hiv/. Accessed 1 August 2007.
30. Temesgen Z, Cainelli F, Vento S. Tipranavir. Drugs Today (Barc) 2005; 41:711-20.
31. Valdez H, McCallister S, Kohlbrenner V, Mayers D. Tipranavir/ritonavir (TPV/r) 500 mg/200 mg BID drives week 24 viral load (VL) below 400 copies/mL when combined with a second active drug (T-20) in protease inhibitor experienced HIV+ patients [abstract WeOa0205]. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment. Geneva: International AIDS Society, 2005.
32. Salazar JC, Cahn P, Della Negra M, et al. Predictors of response to TPV/r in pediatric patients: results of PACTG1051/BI1182.14 [abstract 733). In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2007.
33. Pierone G, Drulak M, Arasteh K, et al. A long-term open-label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir (TPV/r) use in HIV-1-infected patients [Abstract WePe6.2C05]. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment. Geneva: International AIDS Society, 2005.
34. Nwando O, Themba B. An open-label steady state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal healthy volunteers [abstract TuPe7.8C01]. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment, Geneva: International AIDS Society, 2005.
35. Washington CB, Duran GE, Man MC, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:203-9.
36. Walmsley S, Leith J, Katlama C, et al. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI1182.51 [abstract WeOrB1236]. In: Program and abstracts of the 15th International AIDS Conference. Geneva: International AIDS Society, 2004.
37. Roszko PJ, Curry K, Brazina B, et al. Standard doses of efavirenz (EFV), zidovudine (ZDV), tenofovir (TDF), and didanosine (ddI) may be given with tipranavir/ritonavir (TPV/r) [abstract 812]. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Geneva: International AIDS Society, 2003.
38. Philips L, Borin MT, Hopkins NK, Daenzer CL, Wang Y. The pharmacokinetics of nucleoside reverse transcriptase inhibitors when coadministered with the HIV protease inhibitor tipranavir in HIV-1 infected patients [abstract 81]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2000.
39. Sabo JP, MacGregor TR, Lamson M, et al. Pharmacokinetics of tipranavir and nevirapine: a pharmacokinetic study in healthy volunteers [abstract 103]. In: Program and abstracts of the HIV DART 2000: Frontiers in Drug Development for Antiretroviral Therapies. 2000.
40. Schöller M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir boosted with ritonavir in healthy subjects [abstract 583]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
41. Gonzalez De Requena D, Calcagno A, Bonora S, et al. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide [abstract 579]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
42. Van Heeswijk R, Sabo JP, MacGregor T, et al. The effect of tipranavir/ritonavir 500mg/200mg bid (TPV/r) on the pharmacokinetics of fluconazole in healthy volunteers [abstract 20]. In: Program and abstracts of the 5th International Workshop on Clinical Pharmacology in HIV Therapy. 2004. Available at: http://www.hivpresentation.com. Accessed 1 August 2007.
43. Van Heeswijk R, Sabo JP, MacGregor T, et al. The pharmacokinetic interaction between single-dose rifabutin and steady state tipranavir/ritonavir 500mg/200mg (TPV/r) in healthy volunteers (abstract A-456]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Alexandria, VA: American Society for Microbiology, 2004.
44. Doyon L, Tremblay C, Wardrop E, et al. Characterization of HIV-1 isolates showing decreased susceptibility to tipranavir and their inhibition by tipranavir containing drug mixtures [abstract 12]. In: Program and abstracts of the 12th International HIV Drug Resistance Workshop. College Park, GA: Informed Horizons, 2003.
45. Doyon L, Tremblay C, Cartier M, Cordingley M. In vitro susceptibility of HIV-1 to tipranavir. Antivir Ther 2002; 7(Suppl. 1):S12.
46. Mayers D, Leith J, Valdez H, et al. Impact of three or four protease mutations at codons 33, 82, 84 and 90 on 2 week virological responses to tipanavir, lopinavir, amprenavir and saquinavir all boosted by ritonavir in phase 2B trial BI 1182.51 [abstract 147]. In: Program and abstracts of the 13th International HIV Drug Resistance Workshop. College Park, GA: Informed Horizons, 2004.
47. Hall D, McCallister S, Neubacher D, Kraft M, Mayers DL. Characterisation of treatment-emergent resistance mutations in two phase II studies of tipranavir (TPV) [abstract 13]. In: Program and abstracts of the 12th International HIV Drug Resistance Workshop. College Park, GA: Informed Horizons, 2003.
48. Baxter JD, Schapiro JM, Boucher CAB, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006; 80:10794-801.
49. Scherer J, Kohlbrenner VM, Hall DB, et al. Mutations associated with cross-resistance to tipranavir in patients previously treated with two or more protease inhibitors. In: Program and abstracts of the 5th European HIV Drug Resistance Workshop. 2007. Available at: http://www.natap.org. Accessed 30 March 2007.
50. Parkin NT, Chappey C. Protease mutations associated with higher or lower than expected tipranavir susceptibility based on the TPV mutation score [abstract 637]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
51. Naeger LK, Struble KA. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS 2007; 21:179-85.
52. Marcelin AG, Masquelier B, Descamps D, et al. Mutations associated to response to boosted tipranavir in HIV-1 infected protease inhibitor-experienced patients [abstract 612]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2007.
53. Bacheler L, Vermeiren H, Winters B, et al. Clinically relevant phenotypic resistance and cross-resistance to tipranavir among recent routine clinical isolates. In: Program and abstracts of the 4th European HIV Drug Resistance Workshop. 2006. Available at: http://www.hivpresentations.org. Accessed 13 May 2006.
54. Van der Borght K, Winters B, Van Craenenbroeck E, et al. Correlation of resistance algorithms for tipranavir susceptibility with response to tipranavir containing regimens in the RESIST trials. In: Program and abstracts of the 5th European HIV Drug Resistance Workshop. 2007. Available at: http://www.natap.org. Accessed 30 March 2007.
55. De Meyer S, Cao-Van K, Lathouwers E, et al. Phenotypic and genotypic profiling of TMC114, lopinavir and tipranavir against PI-resistant HIV-1 clinical isolates [abstract 42]. In: Program and abstracts of the 4th European HIV Drug Resistance Workshop. 2006. Available at: http://www. hivpresentations.org. Accessed 13 May 2006.
56. Elston RC, Kuritzkes DR, Bethell R. An investigation into the influence of the tipranavir-associated V82L/T mutations on the susceptibility to darunavir and brecanavir. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections [abstract 602]. Alexandria, VA: Foundation for Retrovirology and Human Health, 2007.